Journal of Nuclear Cardiology

, Volume 15, Issue 3, pp 329–336 | Cite as

Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial

  • Brian R. Leaker
  • B. O’Connor
  • Trevor T. Hansel
  • Peter J. Barnes
  • Lixen Meng
  • Vandana S. Mathur
  • Hsiao D. Lieu
Original Articles


Background. Patients with reactive airways are at risk for adenosine-induced bronchocon-striction, mediated via A2B and/or A3 adenosine receptors.

Methods and Results. To examine the effects of regadenoson, a selective adenosine A2A receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV1) at each tested time point relative to the baseline FEV1 was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV1 reduction (−36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo.

Conclusions. In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.

Key Words

Reactive airways spirometry pulmonary function test stress test adenosine receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burkhart KK. Respiratory failure following adenosine administration. Am J Emerg Med 1993;11:249–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Drake I, Routledge PA, Richards R. Bronchospasm induced by intravenous adenosine. Hum Exp Toxicol 1994;13:263–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Adenoscan (adenosine injection) [full prescribing information]. Deerfield (IL): Fujisawa Healthcare; 2004.Google Scholar
  4. 4.
    Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: An A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004;172:7726–33.PubMedGoogle Scholar
  5. 5.
    Feoktistov I, Biaggioni I. Role of adenosine in asthma. Drug Dev Res 1996;39:333–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 1998;19:148–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Fan M, Qin W, Mustafa SJ. Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol 2003;284:L1012–9.PubMedGoogle Scholar
  8. 8.
    Cerqueira M, Nguyen N, Staehr P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol 2008 (in press).Google Scholar
  9. 9.
    Baraldi E, Santuz P, Magagnin G, Filippone M, Zacchello F. Effect of disodium cromoglycate on ventilation and gas exchange during exercise in asthmatic children with a postexertion FEV1 fall less than 15 percent. Chest 1994;106:1083–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819–23.PubMedCrossRefGoogle Scholar
  11. 11.
    ADVAIR (fluticasone propionate and salmeterol) [full prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2006.Google Scholar
  12. 12.
    Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Fardon TC, Hodge MR, Lipworth BJ. Evaluation of an abbreviated adenosine monophosphate bronchial challenge. Chest 2005;127:2222–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Global strategy for asthma management and prevention. Global Initiative for Asthma Executive and Science Committees; 2006 Available from: URL: Scholar
  15. 15.
    Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Balan KK, Critchley M. Is the dyspnea during adenosine cardiac stress test caused by bronchospasm? Am Heart J 2001;142:142–5.PubMedCrossRefGoogle Scholar
  17. 17.
    National Asthma Education and Prevention Program clinical practice guidelines. Guidelines for the diagnosis and management of asthma. NIH publication 97-4051. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1997.Google Scholar
  18. 18.
    Gong H Jr, Simmons MS, Tashkin DP, Hui KK, Lee EY. Bronchodilator effects of caffeine in coffee. A dose-response study of asthmatic subjects. Chest 1986;89:335–42.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2003

Authors and Affiliations

  • Brian R. Leaker
    • 1
  • B. O’Connor
    • 1
  • Trevor T. Hansel
    • 1
  • Peter J. Barnes
    • 1
  • Lixen Meng
    • 2
  • Vandana S. Mathur
    • 3
  • Hsiao D. Lieu
    • 3
  1. 1.From the Pulmonology, Heart and Lung CentreLondonEngland
  2. 2.BiostatisticsCV TherapeuticsPalo Alto
  3. 3.Clinical ResearchCV TherapeuticsPalo Alto

Personalised recommendations